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ABSTRACT
Background: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently
(5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve genotype (GT) 3a patients
when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA
treatment response, since it possesses a high fold in vitro resistance to daclatasvir (DCV) and velpatas-
vir (VEL) in GT 3. We investigated the effect of baseline Y93H in patients with GT 3a infection on treat-
ment outcome, with or without resistance-based DAA-treatment during 2014–2017.
Patients/Methods: Treatment in the intervention group (n¼ 130) was tailored to baseline resistance-
findings by population-sequencing method. Detection of baseline Y93H above 20% prompted a pro-
longed treatment duration of NS5A-inhibitor and sofosbuvir (SOF) and/or addition of ribavirin (RBV).
Patients without baseline Y93H in the intervention group and all patients in the control group (n¼ 78)
received recommended standard DAA-treatment.
Results: A higher sustained virologic response rate (SVR) in the intervention group was shown com-
pared to the control group at 95.4% (124/130) and 88.5% (69/78), respectively (p¼ .06). All five
patients with baseline Y93H in the intervention group achieved SVR with personalised treatment
based on results from resistance testing; either with the addition of RBV or prolonged treatment dur-
ation (24w). In the control group, 2/4 patients with Y93H at baseline treated with ledipasvir/SOF/RBV
or DCV/SOF without RBV, failed treatment.
Conclusion: The results from this real-life study are in accordance with the findings of the randomised
controlled trials in 2015 and the EASL-guidelines of 2016, thus, baseline Y93H impacts on DCV and
VEL treatment outcome.
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Hepatitis C virus (HCV) infection is considered the leading
cause of liver cancer and liver transplantations in the
Western world [1]. Worldwide, an estimated 71 million peo-
ple are living with viraemic HCV infection [2]. In Sweden and
Norway, about 0.4–0.5% of the population is infected with
HCV, which approximately relates to 45,000 and 20,000 indi-
viduals, respectively [3–5]. HCV is classified into seven geno-
types (GT) and >100 subtypes [6]. The most common GT in
Sweden is 1a, followed by GT 3a [7], while in Norway GT 3a
is the most common, followed by 1a [8].
Recently, HCV treatment has undergone a remarkable
change and fixed-dose combinations of direct acting antivi-
rals (DAAs) have replaced the traditional interferon (IFN)-
based treatment. The DAAs can be classified into four
classes, targeting three nonstructural proteins in HCV: NS3/
4A protease inhibitors, NS5A inhibitors, and nucleoside and
non-nucleoside inhibitors of the RNA-dependent NS5B
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polymerase [9]. Using the latest approved drug combina-
tions, a complete cure is possible with sustained virologic
response (SVR) rates above 95%.The SVR rates have been
somewhat lower for GT 3 compared to the other GTs [10].
Almost all patients who fail treatment acquire resistance-
associated substitutions (RASs), e.g., NS5A RAS that will per-
sist for years [9]. Even treatment-naïve patients could have
RASs against currently approved DAAs, i.e., resistance at
baseline [10,11]. Pre-existence of NS5A RASs with high fold
resistance, together with other negative factors, such as high
fibrosis stage, GT 3, or previous treatment with non-NS5A
DAAs, could reduce the efficacy of DAAs [10,12].
RASs can be detected by population (Sanger) sequencing
and next generation sequencing (NGS) methods. The Sanger
method carries a 15–20% cut-off level for detecting RAS in
the viral population, compared to 1% with NGS. However,
the consensus is to recommend a cut-off level of 10–20% for
detecting RASs within the HCV quasispecies, in order to be
of clinical relevance [10,13,14].
The NS5A RAS Y93H mutation/polymorphism is found
quite often (5–10%) at baseline in DAA-treatment-naïve
patients with GT 3 (with regard to subtype 3a) using the
population sequencing method [15]. This RAS possesses a
high fold in vitro resistance of >2000 to daclatasvir (DCV) and
>700 to velpatasvir (VEL) used for treatment of GT 3 infection
[16–18]. This was further revealed in clinical studies, the ALLY-
3 study showed that 33% without liver cirrhosis and 75% with
liver cirrhosis of the GT 3 patients with baseline RAS Y93H
failed 12-week treatment with DCV plus sofosbuvir (SOF) [19].
In the ASTRAL-3 study, which evaluated 12weeks of VEL/SOF
treatment, 4 out of 10 non-SVR patients had the Y93H muta-
tion at baseline, and all non-SVR patients had Y93H at relapse
[20]. In another study, it was shown that baseline Y93H was
associated with lower SVR rates for GT3, in particular for
patients with cirrhosis [21]. Furthermore, it has recently been
demonstrated that addition of RBV with SOF/VEL was benefi-
cial for treatment of GT3 with cirrhosis [22].
Another NS5A RAS, A30K, is found at a similar level
(5–10%) as a common baseline polymorphism in GT 3
patients. It’s in vitro resistance in GT 3a replicon assay
towards DCV and VEL is in the fold ranges of 50 [16,17].
At the initiation of this study there were no available
guidelines regarding baseline resistance testing before DAA
treatment. The aim of this real-life study was to investigate
the impact of Y93H at baseline on treatment outcome in GT
3 infected patients treated with DAAs, i.e., the intervention
group was guided by baseline resistance testing and the
control group was based on national guidelines without
baseline resistance testing. The A30K RAS was also investi-
gated, but only in the later phases as it was not considered
as a clinically relevant RAS in 2014–2015. Known factors
influencing treatment outcome were also evaluated.
Material and methods
Patients and treatment
Patients were consecutively included in this real-life, open
label, nonrandomised Nordic multicenter study, consisting of
an intervention group and a control group. The inclusion
period for the intervention group was from 2 October 2014
to 5 December 2017 (when DCV/SOF or VEL/SOF were the
recommended treatment regimes), and for the control group
from April 2014 to 17 November 2016, Thus, the inclusion
period was one year shorter for the control group in com-
parison to the intervention group and consequently no treat-
ments with VEL/SOF (launched autumn 2016) in the control
group. This was mainly due to the new EASL guidelines for
baseline resistance testing, which became endorsed after 22
September 2016. Patients with chronic HCV GT 3a infection
from Uppsala and Tromsø received treatment based on the
results from resistance testing prior to treatment initiation
(intervention group). The control group consisted of patients
from Bodø, Falun, Stockholm and €Orebro, who received
treatment according to national guidelines [23–26] without
previous drug resistance testing.
In the intervention group (n¼ 130), treatment was
adjusted to baseline resistance findings detected by the
population sequencing method. Detection of baseline Y93H
prompted either prolonged treatment duration (during 2014-
16 DCV/SOF and during 2017 VEL/SOF) and/or addition of
ribavirin (RBV) at the responsible MD’s discretion. At one
occasion in 2016, 12weeks SOF plus pegylated (PEG)-IFN
with RBV was used. Patients without baseline Y93H in the
intervention group and all patients in the control group
(n¼ 78) received recommended standard DAA-treatment
according to the National Boards. Note that A30K was not
initially implemented in the intervention group as it was an
unknown baseline RAS at the start of the study in 2014.
Samples for NS5A resistance analysis in the intervention
group were analysed consecutively in routine diagnostics,
while samples from the control group were analysed
retrospectively.
Resistance analysis for emerging NS5A RAS was performed
on all non-SVR patients at the time of relapse in the inter-
vention group and retrospectively for the patients in the
control group.
The inclusion criteria were: infection with HCV GT 3a;
18 years of age; informed consent; and treatment according
to Swedish and Norwegian consensus recommendations.
Patients previously treated with SOF plus ribavirin or other
DAAs were excluded.
Liver elasticity (kPa) was measured with FibroScanVR 502
(Echosens, France) (Swedish study sites) and FibroScanVR 402
(Echosens, France; Norwegian study sites) by experienced
nurses or doctors. For patients who had undergone a liver
biopsy, the Metavir score was recorded [27]. Presence of cir-
rhosis was determined by FibroScan >12.5 kPa [28] or
Metavir fibrosis score 4 in liver biopsy. The Child-Pugh score
was estimated on the basis of available information from
clinical examination, biochemical results and ultrasound.
Patient data was extracted from the medical records by the
responsible MD at each study site, anonymised and trans-
ferred to a joint database.
SVR was defined as undetectable HCV RNA 12weeks after
the end of treatment. Non-SVR was regarded as either viral
breakthrough (a negative viral load nadir followed by a
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positive HCV RNA level during therapy), nonresponse
(increase in HCV RNA levels after initial decrease during treat-
ment) or viral relapse (nondetectable viral load at the end of
treatment followed by an increase in HCV RNA-level
beyond therapy).
The primary objective was to study the treatment efficacy
in the intervention group compared to the control group,
with respect to the proportion of patients achieving SVR.
Secondary objectives included to determine: (1) the propor-
tion of patients with NS5A baseline Y93H and A30K RASs; (2)
the proportion of patients with these baseline NS5A RASs
experiencing viral breakthrough or relapse; and (3) the pro-
portion of patients with baseline NS5A RASs not experienc-
ing viral breakthrough or relapse.
Laboratory methods
Resistance testing of RASs (baseline and emerging) was per-
formed at the Department of Clinical Microbiology at
Akademiska Hospital, Uppsala and was performed on all
available samples at baseline, i.e., on samples collected prior
to treatment initiation and at treatment failure. Viral gene
from patient samples was amplified by the Nested PCR
method and then sequenced by the Sanger sequencing
method (population sequencing). This pan-genotypic NS5A
resistance analysis protocol has been published previously
[29]. In brief, RNA extraction from plasma samples was done
using NucliSENSVR easyMAGTM system (BioMerieux, Marcy-
l’Etoile, France). cDNA was synthesised from RNA template
with SuperScriptTM III Reverse Transcriptase (InvitrogenTM,
Thermo Fisher, Waltham, MA, USA) using random hexamers.
First round PCR and nested PCR were performed with in-
house primers targeting parts of the NS5A-regions using the
Taq PCR Master Mix (QIAgen, Hilden, Germany) [29]. The
amplicons were verified by agarose-gel electrophoresis. PCR-
positive samples were purified using QIAquickVR PCR
Purification Kit (QIAgen, Hilden, Germany) before they were
sent for sequencing.
The first two rounds of PCR amplification protocols pre-
ceding the sequencing step were revised on samples
included in this study as of Q1 2017. Synthesis of cDNA and
first round of PCR was done using Takara PrimeScriptTM One
Step RT-PCR Kit Ver.2 (Takara BIO Inc, Kusatsu, Shiga prefec-
ture, Japan). Nested PCR was performed as previously [29].
The nested PCR products were verified by e-GelVR 2% agarose
electrophoresis (Invitrogen, ThermoFischer Scientific,






Scientific, Waltham, MA, USA).
The purified products were, at the start of this study, sent
to the Uppsala Genome Centre and as of Q3 2017 to
EurofinsGenomics, Ebersberg, Germany for capillary electro-




Waltham, MA, USA) using the same primer pair used in the
nested PCR.
Sequence analysis
Population-based sequencing generates a consensus
sequence of the viral quasispecies with a sensitivity of
approximately 20% for (minority) variants, recognised as
mixed peaks in the electropherogram. The NS5A sequence
results were aligned and analysed using SeqScapeVR Software
v2.6 (Applied Biosystems
TM
, Thermo Fisher Scientific,
Waltham, MA, USA) to generate consensus sequences. The
NS5A sequence of HCV GT1a H77 strain (accession number:
NC_004102.1) was used as a reference template to which the
sample sequences were aligned. To simplify, we considered
this reference GT 1a template suitable for GT 3 during
the analysis with the Seqscape software as described in a
previous reports [7,29,30]. However, later on, the results
were compared with GT 3a specific reference strain:
D17763 (NZL1).
To detect relevant substitutions and evaluate their impli-
cations, the consensus sequences were submitted in the
web-based mutation detection algorithm, Geno2Pheno [hcv]
0.92 (G2P) [30]. Substitutions scored by G2P were further
interpreted as clinically relevant RASs by relating scores with
EASL guidelines 2016 and 2018, in addition to RASs reported
to bear impact on DAA treatment outcome in vitro and/or in
vivo in literatures [10,18,31]. In this study, the NS5A RASs
Y93H and A30K were defined as relevant for GT3 as reported
in the literature [14].
HCV-RNA quantification of the patient samples was per-
formed at the Department of Clinical Microbiology at
Uppsala Akademiska Hospital (2014–2017: COBASVR
AmpliPrep/TaqManVR HCVQuantitative Test (Roche, Basel,
Switzerland), v2.0 with a LOQ of 15 IU/mL and 2017 onwards
Abbott m2000 HCV Viral Load Assay (Abbott Laboratories,
Chicago, IL, USA) with a LOQ of 12 IU/mL. and at the
Department of Microbiology, University Hospital of North
Norway, Tromsø, Norway (ROCHE RT-PCR, Cobas Amplicor
Hepatitis C Viral Polymerase Chain Reaction, Roche Molecular
System Inc., Branchburg NJ, USA). All protocols used were
performed according to the manufacturer’s instructions.
Statistics
The null hypothesis of this study was that the SVR12 rate
was equal in the intervention and control groups. The basic
statistical computing was done in MicrosoftVR ExcelVR 2013
(Microsoft Office professional plus 2013, Microsoft
Corporation) and in Statistical Package for Societal Sciences,
version 24 (IBM Corp., Armonk, NY, USA). The Chi-square-test
was used to test the differences between groups (or Fishers
exact test if expected cell count was small). A two-tailed p
value <.05 was considered significant.
Ethics
The protocol of this multicentre study was in compliance
with the Helsinki Declaration. The regional committee of
medical research ethics, Committee in Uppsala (Dnr: 2013/
185, Dnr: 2013/185/1 and Dnr: 2013/185/2) and the Data
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Protection Official at The University Hospital of Northern
Norway (Nr. 0574) approved this study. All participants
received written information and the opportunity to with-
draw from this study.
Results
Patient baseline characteristics
In total, 226 patients with HCV GT3, 141 in the intervention
group and 85 in the control group were assessed to be eli-
gible for the study. Eleven patients from the intervention
group were omitted from further analyses: one refrained
from participation, one was re-infected with GT 1a, two were
lost to follow-up, two could not give informed consent, and
baseline resistance results could not be obtained from five of
the patients. In the control group, seven patients were omit-
ted; one deceased before SVR and six had no results from
baseline resistance analysis. Thus, week 12 follow-up data
were obtained from 208 patients; 130 in the intervention
group and 78 in the control group (Figure 1).
Detailed demographic and baseline clinical characteristics
are described in Table 1. Most patients were men, 73.1% (95/
130) and 66.7% (52/78) in the intervention and control
groups, respectively, and the majority was treatment-naïve
to previous PEG-IFN/RBV regimen, 76.9% (100/130) and
59.0% (46/78) in the intervention and control groups,
respectively. Amongst the patients who were PEG-IFN/RBV
treatment-experienced, 77.4% (24/31) in the control group
had response-relapse compared to 60.7% (17/28) in the inter-
vention group. The median age at start of treatment was 55
and 52 years in the intervention and control groups, respect-
ively. The distribution of patients with cirrhosis was 37.7%
(49/130) and 61.5% (48/78) in the intervention and control
groups, respectively. Median viral load at start of treatment
was similar in both groups.
Most cirrhotic patients in both groups were Child-Pugh
class A (data not shown).
Table 2 describes treatment characteristics. The distribu-
tion and variety of treatment regimens were higher in the
intervention group since patients were included in this group
also during 2017 when more DAAs were available. While the
great majority of the patients in the control group were
administered DCV/SOF (93.6%, 73/78), the remaining were
administered ledipasvir (LED) plus SOF. Among the patients
in the intervention group, 47.7% (62/130) were treated with
DCV/SOF, 10.0% (13/130) were treated with LED/SOF, and
furthermore, only patients in the intervention group were
treated with VEL/SOF (41.5%, 54/130). Of the patients on
VEL/SOF-treatment, 29.6% (16/54) also had RBV included in
the treatment regime (data not shown). Most of the patients
in both groups received treatment for 12weeks, but it was
more common in the intervention group compared to the
control group, 76.9% (100/130) and 53.8% (42/78), respect-
ively (p< .001). Simultaneous prolonged treatment of
24weeks and addition of RBV was administered to 32.1%
(25/78) in the control group compared to only 3.8% (5/130)
in the intervention group (data not shown).
Baseline RASs
The prevalence of baseline Y93H RAS was similar in both the
intervention and control groups; 3.8% (5/130) and 5.1% (4/
78), respectively, and baseline A30K prevalence was 3.8% (5/
130) and 2.6% (2/78), respectively. The prevalence of baseline
Y93H in terms of country/cohort was also similar with 4.9%
(6/122) and 3.5% (3/86) in the Swedish and Norwegian
cohorts, respectively (Table 3). In contrast, only one baseline
Baseline resistance 
analysis
Intervention group  
Uppsala, Tromsø
Assessed for eligibility, N=141
Control group  
Bodø, Falun, Stockholm, Örebro
Assessed for eligibility, N= 85
Excluded, n=11
One refrained from participation
One was reinfected with GT1a 
Two were lost to follow-up
Two could not give informed consent

















One is diseased before SVR 
Six did not have results from baseline 
 resistance analysis
Figure 1. Flowchart of patients included in the study. Baseline resistance testing in the control group was performed retrospectively.
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A30K was found in the Swedish cohort as all the other A30K
was found in the Norwegian patients, 0.8% (1/122) and 7.0%
(6/86), respectively. Detailed description of clinical character-
istics of the patients harbouring baseline RASs A30K and
Y93H are summarised in Table 3.
Of the five patients with baseline A30K in the intervention
group, one was detected in a patient who subsequently
relapsed. In the control group, prevalence of A30K was lower
but found in one of the two patients who relapsed.
All five patients with baseline Y93H in the intervention
group achieved SVR with treatment based on results from
the resistance testing. These patients were treated with
either 24weeks DCV/SOF or LED/SOF treatment without RBV,
12weeks VEL/SOF with RBV, or 12weeks SOF plus PEG-IFN
with RBV.
One patient with A30K in the intervention group did not
have the treatment adjusted since the A30K was not consid-
ered a clinically relevant NS5A RAS at the time of start of
treatment in 2014 (and during 2015). This patient was
treated 12weeks with DCV/SOF but subsequently failed
and relapsed.
In the control group, 50.0% (2/4) of the patients with
Y93H at baseline failed treatment and relapsed. These two
patients were treated with LED/SOF and RBV for 16weeks
and DCV/SOF without RBV for 24weeks, respectively (Tables
3 and 4).
In total, 15 patients failed to achieve SVR12, four of them
had baseline RAS (three in the control group; one in the
intervention group). The main reason for non-SVR was viral
relapse, however, in two patients viral breakthrough ensued,
and one patient was nonresponding. In three of these
patients, one A30K and two Y93H were detected at baseline
in the control group. One A30K was detected in the inter-
vention group (Table 4).
SVR12 rates
SVR12 rates were consistently higher in the intervention
group compared to the control group (Figure 2). The most
distinct differences between the intervention and control
groups are: (1) an overall SVR rate of 95.4% (124/130) and
88.5% (69/78), respectively (p¼ .06); (2) a SVR rate in patients
with baseline Y93H of 100% (5/5) and 50% (2/4), respectively
(p¼ .07); and (3) a SVR rate in 12-week treatment of 98%
(98/100) and 90.2% (38/42), respectively (p¼ .04).
Of the patients in the intervention group who received a
12-week treatment and relapsed, one was treatment-naïve
and noncirrhotic but harboured baseline A30K, and another
had cirrhosis but did not have any baseline RAS but had
failed previous treatment history with PEG-IFN/RBV. Neither
had RBV added to their regimens with DCV plus SOF. In the
control group, 4/42 failed 12-week treatment regimens. All
were male and had previous treatment history with PEG-IFN/
RBV; three had relapsed and one was nonresponding. Three
were cirrhotic and had 12weeks of DCV plus SOF and RBV.
One was noncirrhotic and did not receive RBV. Subsequent
Table 1. Genotype 3 patient baseline characteristics.
Intervention group (n¼ 130) Control group (n¼ 78) p Value
Median age, yr. (range) 55 (22–77) 52 (25–67)
Male, n (%) 95 (73.1) 52 (66.7) .33
Cirrhosis, n (%) 49 (37.7) 48 (61.5) .00085
Median HCV RNA, log10 IU/ml (range) 6.1 (3.2–7.9) 6.0 (4.3–7.2)
Beseline Y93H (%) 5 (3.8) 4 (5.1) .66
Baseline A30K (%) 5 (3.8) 2 (2.6) .62
Previous HCV treatmenta, n (%)
Treatment- naïve 100 (76.9) 46 (59.0) .0061
Nonresponder 1 (0.8) 4 (5.1)
Partial responder 6 (4.6) 2 (2.6)
Relapse 17 (13.1) 24 (30.8) .0019
Intolerant 4 (3.1) 1 (1.3)
NA 2 (1.5) 1 (1.3)
aTreatment referring pegylated interferon (Peg/INF) plus ribavirin.
Table 2. Treatment characteristics of the GT3 patients.
Intervention group (n¼ 130) Control group (n¼ 78) p Value
Treatment regime, n (%)
Daclatasvirþ sofosbuvir 62 (47.7) 73 (93.6) 1.89E–11
Velpatasvirþ sofosbuvir 54 (41.5) –
Ledipasvirþ sofosbuvir 13 (10.0) 5 (6.4) .37
Sofosbuvirþ PEG-INFþ ribavirin 1 (0.8) –
Treatment duration, wk
4 wka 1 (0.8) –
8 wk 1 (0.8) –
12 wk 100 (76.9) 42 (53.8) .00054
16 wk 13 (10.0) 8 (10.3)
20 wk 3 (2.3) –
24 wk 12 (9.2) 28 (35.9) 2.0E–06
Addition of ribavirin, n (%) 50 (38.5) 54 (69.2) 1.73E–05
aTreatment was discontinued in one patient due to noncompliance.
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analyses for presence of baseline RAS showed that one of
them had A30K at baseline (Table 4).
Discussion
This Nordic multicenter study from April 2014 to December
2017 was performed when data on optimal regimens were
emerging and guidelines were rapidly changing. For GT
3 treatment, the EASL guidelines recommended DCV plus
SOF during 2014–2015 and a change to VEL/SOF in
2016–2017. Thereby, this study was conducted prior to
recently approved (in Sweden January 2018 and in Norway
February 2018) medications [glecaprevir (GLE)/pibrentasvir
(PIB) and VEL/SOF plus voxilaprevir (VOX)]. Thus, these regi-
mens have in a global perspective greatly improved the SVR
rates, even for GT 3 in presence of NS5A RASs. This is mainly
due to the inclusion of GLE or VOX, which are effective NS3
protease inhibitors against GT 3.
When we started this real-life study, the knowledge on
outcome of baseline NS5A RAS in GT 3 treatment was very
limited. However, we suspected that the clinically most rele-
vant RAS in GT 3 should be Y93H, which according to in vitro
data from the literature confers a high level of resistance to
DCV and VEL, where the fold-change values in resistance
compared to GT 3a wild type replicon are 2100 and 700 fold,
respectively [16,17]. In the ALLY-3 and the ASTRAL-3 clinical
studies, it was later shown that the Y93H in GT 3 was associ-
ated with lower SVR rates to treatment with DCV/SOF and
VEL/SOF, especially in cirrhosis patients with baseline Y93H
[19,20]. Furthermore, the natural prevalence of Y93H is as
high as 5–10% in GT 3 patients with no prior exposure to
NS5A treatment [10]. Thereby, since September 2016 it is
stated in the EASL guidelines that physicians who have easy
access to reliable resistance tests can use baseline testing of
Y93H in GT 3 patients to guide their decisions prior to treat-
ment with VEL/SOF [14,32]. In case of baseline Y93H findings,
these guidelines recommend the addition of RBV and/or
extended treatment duration, which were actually the same
recommendations (during 2014–2017) for retreatment of GT
3 patients with previous NS5A DAA-failure. In the recent
report from the surveillance system against Antivirals in
Norway (RAVN), resistance testing of Y93H at baseline is rec-
ommended in patients with GT 3 and cirrhosis [33].
It was, therefore, relevant for the study group, as early as
2014, to evaluate treatment outcome based on baseline ana-
lysis of Y93H. As displayed in Table 3, all five patients with
baseline Y93H in the intervention group achieved SVR with
personalised resistance-based treatment. In the control
group, 2/4 patients with Y93H at baseline, one treated for
16weeks with LED/SOF and RBV and the other 24weeks
with DCV/SOF, failed treatment. Thereby, Y93H appeared to
have a negative impact on treatment outcome (p¼ .073).
However, because of a lower prevalence of baseline Y93H
than expected and the limited sample sizes this could not be
statistically determined.
In our study, an overall higher SVR was shown in the
intervention group compared to the control group with val-
ues at 95.4% (124/130) and 88.5% (69/78), respectively
(p¼ .06). However, there could be several confounding fac-
tors for the results in the intervention group compared to
the control group. As shown in Table 1, some known nega-
tive predictors for SVR outcome were found in the control
group compared to the intervention group in terms of the
proportion of treatment naive patients (59.0% versus 76.9%),
and more patients with cirrhosis (61.5% versus 37.7%).
However, negative factors were also found in the interven-
tion group, which had a higher rate of male patients; 73.1%
compared to 66.7% in the control group, and a lower pro-
portion of patients receiving 24weeks of treatment; 9.2%
compared to 35.9% in the control group. In addition, the
newer treatment regimen VEL/SOF was used in the interven-
tion group (41.5%) and not at all in the control group.
However, it has been shown in a recent large real-life study
of 2824 GT 3 patients that the chance of obtaining SVR was
Figure 2. Sustained virologic response rates (SVR) in the intervention and control groups. Treatment period for the intervention group was from 2 October 2014 to
5 December 2017, and for the control group from 10 April 2014 to 17 November 2016. SVR rates in the intervention group (blue bars) and the control group
(orange bars).
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the same irrespective of whether a patient received DCV/SOF
or VEL/SOF [34]. It should also be noted that a few patients
in our study, thirteen in the intervention group and five in
the control group, were prescribed LED/SOF. This was done
in 2014 and early 2015, before DCV was available in Norway.
At this time, it was still not known that LED is less potent
against GT 3 than DCV and VEL [14]. Despite the many dis-
similarities between the intervention and control groups, still
higher SVR rates for the intervention groups than for controls
were found for all different parameters displayed in Figure 2.
Interestingly, even when data are adjusted for inclusion-
period, the specified data from both groups are confined to
treatment start between 2014 and 2016, SVR-rates in all
examined parameters still show a tendency to be higher in
the intervention group than in the control group
(Supporting Information, Figure S1). Correspondingly, all
other parameters (i.e. age, sex, previous treatment experi-
ence, prevalence of baseline Y93H and A30K, proportion of
cirrhotic patients, proportion of prolonged treatment dur-
ation and the addition of RBV) included in this study remain
very similar in both groups even after adjustment of time
period. It should be mentioned that ten patients in the inter-
vention group received VEL/SOF, compared to none in the
control group during the matched period (data not shown).
The NS5A RAS A30K exists as a polymorphism in GT 3 in
the same prevalence range 5–10% as Y93H. This RAS in GT
3a replicon assay confers resistance levels of 44 fold to DCV
and 50 fold to VEL [16,17]. Even though these resistance lev-
els are lower than for Y93H, it could be a negative factor in
patients who are difficult to treat, e.g., with severe cirrhosis.
Combination of HCV RASs can often confer greater level of
phenotypic resistance, however, we did not detect the com-
bination of A30K and Y93H, neither at baseline or at treat-
ment failure, which is in accordance with a recent report
[35]. At the beginning of our study during 2014–2015, the
RAS A30K was not considered a clinically relevant NS5A RAS
but during 2016 the intervention group had its regimen tail-
ored to this baseline RAS. It could be noted that a clinical
study of the recently approved GLE/PIB treatment suggests a
negative effect of baseline A30K. In treatment-experienced
(PEG-IFN or SOF) GT 3 patients without cirrhosis who
received 12weeks of GLE/PIB treatment, significant lower
SVR rate (25%) was observed for those patients with A30K at
baseline, compared to those without A30K at baseline (SVR
96%) [36].
The current Swedish and Norwegian recommendations for
first-line treatment of treatment-naive GT 3 patients is, due
to cost-effectiveness considerations, still VEL/SOF [26,37].
Thereby, baseline resistance testing in treatment of GT 3
may also, in addition to optimising responses and economic
consequences, lead to less RBV use and shorter durations
than dosing purely based on disease characteristics such as
treatment experiences or cirrhosis.
Conclusion
In this real-life study conducted in Q2 2014 to Q4 2017, we
found a low prevalence of baseline Y93H RAS in HCV
genotype 3 in Sweden and Norway. Even though a trend
was observed for Y93H being a negative predictor for DCV/
SOF or VEL/SOF treatment outcome (p¼ .07), it could not be
statistically determined, probably due to the small sample
sizes. However, the findings are in line with the randomised
controlled trials (ALLY-3 and ASTRAL-3) and the EASL-guide-
lines of 2016 and 2018. This could, therefore, have positive
implications for the latest approved regimes, GLE/PIB and
VEL/SOF/VOX, combinations that are known to be more
potent against Y93H. However, these regimes often are more
expensive than VEL/SOF and mainly considered as retreat-
ment options. Since the resistance analysis cost per individ-
ual, even today, is 20–50 fold lower than the cost of current
DAA-treatment, selection of cost-effective treatment combi-
nations/duration should still be of importance, both in a per-
spective of evidence-based healthcare delivery, resistance-
surveillance, and for the individual patient to avoid relapse
with uncertain retreatment options.
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